



OPEN

# Meta-Analysis of Infectious Agents and Depression

SUBJECT AREAS:

RISK FACTORS  
DEPRESSIONXiao Wang<sup>1,2\*</sup>, Liang Zhang<sup>1,2,3\*</sup>, Yang Lei<sup>1,2,3\*</sup>, Xia Liu<sup>1,2,3\*</sup>, Xinyu Zhou<sup>1,2,3</sup>, Yiyun Liu<sup>1,2,3</sup>,  
Mingju Wang<sup>1,2,3</sup>, Liu Yang<sup>1,2</sup>, Lujun Zhang<sup>1,2</sup>, Songhua Fan<sup>1,2,3</sup> & Peng Xie<sup>1,2,3</sup>Received  
11 November 2013Accepted  
12 March 2014Published  
31 March 2014Correspondence and  
requests for materials  
should be addressed to  
P.X. (xiepeng@cqmu.  
edu.cn)\* These authors  
contributed equally to  
this work.<sup>1</sup>Institute of Neuroscience, Chongqing Medical University, Chongqing, China, <sup>2</sup>Chongqing Key Laboratory of Neurobiology, Chongqing, China, <sup>3</sup>Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Depression is a debilitating psychiatric disorder and a growing global public health issue. However, the relationships between microbial infections and depression remains uncertain. A computerized literature search of Medline, ISI Web of Knowledge, PsycINFO, and the Cochrane Library was conducted up to May 2013, and 6362 studies were initially identified for screening. Case-control studies detected biomarker of microorganism were included. Based on inclusion and exclusion criteria, 28 studies were finally included to compare the detection of 16 infectious agents in unipolar depressed patients and healthy controls with a positive incident being defined as a positive biochemical marker of microbial infection. A customized form was used for data extraction. Pooled analysis revealed that the majority of the 16 infectious agents were not significantly associated with depression. However, there were statistically significant associations between depression and infection with Borna disease virus, herpes simplex virus-1, varicella zoster virus, Epstein-Barr virus, and *Chlamydia trachomatis*.

Depression is a syndrome characterized by a sad mood exceeding normal sadness or grief, and major depressive disorder (MDD, major depression) has been associated with considerable morbidity and mortality<sup>1</sup> and has been projected to become the second-leading cause of disability worldwide by 2020 after ischemic heart disease<sup>2</sup>. Recent studies have implicated several genes in the development of depression<sup>3</sup>, although the search for specific genes that confer this risk has been frustrating, as no genetic abnormality has been identified with any certainty<sup>4</sup>. In addition, several studies have suggested that environmental factors also contribute to an increased risk of depression, including exposure to poverty<sup>5</sup>, toxic factors<sup>6</sup>, stress<sup>7</sup>, and infectious agents<sup>8</sup>.


There is a long-standing belief that infectious agents can produce depression<sup>8</sup>; for example, infections occurring during prenatal and perinatal stages have produced serious neuropsychiatric consequences<sup>9</sup>, and early cross-sectional studies have demonstrated significantly elevated antibody titers against herpes simplex virus (HSV) in depressed patients<sup>10</sup>. Therefore, there may be an association between certain infectious agents and the development of depression that could provide a means by which to improve both depression outcomes and prevention.

Despite the substantial number of studies on this subject, contradictory findings have arisen. Early clinical studies supported an association of raised antibody titers against HSV<sup>10</sup> and Epstein-Barr virus<sup>11</sup> with depression. However, opposing results have also been reported that reveal no significant association between antibodies to HSV<sup>12</sup>, influenza<sup>13</sup>, or neurotropic viruses<sup>14</sup> with depression. Therefore, this study aims to systematically analyze the current evidence regarding associations between a set of infectious agents and depression.

## Results

According to aforementioned inclusion and exclusion criteria, 28 studies were finally considered eligible for inclusion in the meta-analysis (Fig. 1, Table 1). Forest plots comparing infections with Borna disease virus (BDV) (Fig. 2), human herpesvirus (HHV, *Herpesviridae*) (Fig. 3), *Chlamydiaceae* (Fig. 4), hepatitis B virus (HBV) (Fig. 5A) and *Toxoplasma gondii* (Fig. 5B) between depressed patients and controls are also provided.

**BDV.** BDV is the most widely-studied infectious agent associated with depression. A total of 15 studies were included, two of which stood out as those of highest weight<sup>15</sup> and quality<sup>16</sup> (Fig. 2, Table 1). The narrowest CI 95% range study was a Bode<sup>17</sup> study on account of the large amount of participants included. The estimated combined OR was 3.25 (CI 95%: 1.61–6.55;  $P = 0.001$ ), indicating a statistically significant association between BDV infection and depression. After performing heterogeneity testing between these studies, the resulting  $\chi^2_{\text{exp}} =$



**Figure 1** | Flow diagram depicting the stages of the systematic review and meta analysis. The number of studies (n) identified, screened, excluded, and included are detailed.

25.96 (14 degrees of freedom,  $P = 0.026$ ) indicated a trend for significant heterogeneity among OR values obtained from different studies. This finding is corroborated by a  $I^2$  coefficient of 46.1% (CI 95%: 0.02–0.71), which indicates that 46.1% of the variability between the OR values obtained from different studies was due to a moderate level of heterogeneity between them (<75%). Using meta-regression, we found that the technique used to detect BDV infection did not influence the OR value ( $P = 0.494$ ). Thus, the OR values of the studies that detected RNA from blood or PBMCs (OR = 8.55, CI 95%: 2.48–29.44) were not significantly different from the OR values obtained in studies in which serum antibodies were detected (OR = 2.39, CI 95%: 1.01–5.66). Begg's and Egger's tests were both performed, and the findings therefrom were not significant ( $P = 0.805$  and  $P = 0.297$ , respectively), indicating no publication bias.

**HHV.** Six HHVs – herpes simplex virus-1 (HSV-1, HHV-1), herpes simplex virus-2 (HSV-2, HHV-2), varicella zoster virus (VZV, HHV-3), Epstein-Barr virus (EBV, HHV-4), cytomegalovirus (CMV, HHV-5), and roseolovirus (HHV-6) – were analyzed in the current study (Fig. 3). As to HSV-1, significant differences were found ( $P = 0.030$ ) from the analysis of four studies that compared HSV-1 infection in depressed patients and healthy controls (Fig. 3A). The Pokorny et al.<sup>12</sup> study was assigned the highest weight. When heterogeneity tests were performed, a  $\chi^2_{\text{exp}} = 5.47$  was obtained with three degrees of freedom and a  $P = 0.140$ , indicating that the differences between the studies can be attributed to randomness. This finding was further corroborated by an  $I^2$  coefficient of 45.2% (CI 95%: 0–0.82), indicating that there was not substantial inconsistency. The Begg's test result was not significant ( $P = 1.000$ ), indicating no publication bias. A similar result was obtained after Egger's test ( $P = 0.986$ ). With respect to VZV, significant differences were found (OR = 2.07; CI 95%: 1.01–4.28;  $P = 0.048$ ) from the analysis of three low-quality studies that compared VZV infection in depressed patients and healthy controls (Fig. 3B). The Lycke et al.<sup>18</sup> study was assigned the highest weight and relative high-quality. After heterogeneity tests, a value of  $\chi^2_{\text{exp}} = 0.39$  with two degrees of freedom, and  $P = 0.821$ , suggested that the differences found between the studies could be due to randomness. This finding was also corroborated by an  $I^2$  coefficient of 0.0% (CI 95%: 0–0.47), indicating that no OR variability was due to study heterogeneity. Both Begg's and Egger's tests were not significant ( $P = 0.117$  and  $P = 0.500$ , respectively),

indicating that there was no publishing bias. With regard to EBV, four studies compared EBV infection in depressed patients and healthy controls (Fig. 3C). The studies were heterogeneous, and the most relevant ones were those by Haeri<sup>19</sup> and Johnson<sup>20</sup> due to their larger sample sizes. When all four studies were combined, an overall OR of 1.99 (CI 95%: 1.21–3.28;  $P = 0.007$ ) was obtained for the association between EBV and depression. Therefore, depression was 1.99 times more frequent in individuals displaying the EBV marker than in individuals who did not. When only studies that used serum antibodies as the EBV infection marker were included, the result remained statistically significant with an OR of 1.96 (CI 95%: 1.18–3.24;  $P = 0.009$ ). When heterogeneity analysis was conducted, a  $\chi^2_{\text{exp}} = 2.16$  was obtained with three degrees of freedom and a  $P = 0.540$ , indicating that the differences between the studies could be due to randomness. This finding was also corroborated by an  $I^2$  coefficient of 0.0% (CI 95%: 0–0.79), indicating that no OR variability was due to study heterogeneity. There was no evident publishing bias, as the Begg's ( $P = 0.497$ ) and Egger's ( $P = 0.730$ ) tests were not significant.

With respect to the other HHVs, no significant differences were found when comparing infection with HSV-2, CMV, or HHV-6 in depressed patients and healthy controls. As to CMV, three studies compared CMV infection by means of antibody or viral DNA in depressed patients and healthy controls (Fig. 3D). The weight of the studies performed in 1974<sup>18</sup> superceeded the other two studies, as it had the largest sample size and highest quality. Significant OR values were not found for any of the studies nor for the combined OR (OR = 1.91; CI 95%: 0.89–4.09;  $P = 0.096$ ). When heterogeneity tests were performed, a  $\chi^2_{\text{exp}} = 0.45$  was obtained with two degrees of freedom and a  $P = 0.799$ , indicating that the differences between the studies can be attributed to randomness. This finding was also corroborated by an  $I^2$  coefficient of 0.0% (CI 95%: 0–0.54), indicating that no OR variability was due to study heterogeneity. The Begg's test result was not significant ( $P = 0.117$ ), indicating no publication bias. A similar result was obtained after Egger's test ( $P = 0.46$ ).

**Chlamydiaeae.** Two studies of similar quality by Fellerhoff et al.<sup>21,22</sup> were included and used blood samples to detect the DNA of three *Chlamydiaeae* species (i.e., *C. trachomatis*, *C. pneumoniae*, and *C. psittaci*) through polymerase chain reaction (PCR) (Fig. 4). A significant association was found for *C. trachomatis* with a wide 95% confidence interval (OR = 11.02; CI 95%: 1.53–79.39;  $P = 0.017$ ; Fig. 4A). However, in the cases of *C. pneumoniae* (OR =



Table 1 | Analysis and Evaluation of Studies Included in the Meta-Analysis

Microorganism	Study	Diagnostic criteria	Sample	Technique	Determination	Descriptive statistics				Inferential statistics			Quality			
						Cases		Controls		OR	95%CI	Weight (%)	S	C	E	Global OR
						+	-	+	-							
BDV	Amsterdam JD et al. (1985) <sup>49</sup>	DSM-III	SE	IFA	Ab	6	120	0	105	11.38	0.63–204.44	4.51	**	*	3.25 (1.61–6.55; P = 0.001)	
	Bode L et al. (1992) <sup>17</sup>	DSM-III	SE	IP	Ab	5	358	11	472	0.60	0.21–1.74	13.38	*	*		
	Fu ZF et al. (1993) <sup>15</sup>	DSM-III-R	SE	WB	Ab	53	85	19	98	3.22	1.77–5.86	16.97	***	**	***	
	Bode L et al. (1995) <sup>30</sup>	DSM-III-R	PBMCs	N-RT-PCR, FCM, IF	RNA, Ag, Ab	2	1	0	10	35.00	1.07–1141.97	3.34	**	**	**	
	Igata-Yi R et al. (1996) <sup>50</sup>	DSM-III-R	PBMCs	N-RT-PCR	RNA	1	5	0	36	19.91	0.72–552.78	3.62	*	**	**	
	Salvatore M et al. (1997) <sup>51</sup>	DSM-III-R	BR	N-RT-PCR	RNA	0	6	0	10	1.62	0.03–91.81	2.60	*	*	*	
	Fukuda K et al. (2001) <sup>52</sup>	DSM-IV	PL	WB, ECLIA, IFAb	RNA	1	24	0	45	5.57	0.22–141.99	3.77	***	**	**	
	Bode L et al. (2001) <sup>29</sup>	DSM-III-R	PL	ELISA	CIC	18	2	21	44	18.86	4.00–88.90	9.94	**	*	*	
	Lebain P et al. (2002) <sup>53</sup>	DSM-IV	SE	IFA	Ab	3	21	45	245	0.78	0.22–2.72	11.98	***	***	***	
	Zou Dezhi et al. (2003) <sup>54</sup>	CCMD-3	PBMCs	RT-qPCR	RNA	1	20	0	60	8.85	0.35–225.97	3.77	**	**	**	
	Wang Zhenhai et al. (2006) <sup>55</sup>	CCMD-3	PBMCs	RT-qPCR	RNA	6	47	0	32	8.89	0.48–163.42	4.46	***	***	**	
	Zhao Libo et al. (2007) <sup>56</sup>	CCMD-3	PBMCs	RT-qPCR	RNA	3	57	0	120	14.67	0.75–288.75	4.30	***	*	**	
	Flower RL et al. (2008) <sup>57</sup>	DSM-IV	PL	ELISA	Ab	5	99	5	214	2.16	0.61–7.64	11.90	**	**	**	
	Na KS et al. (2009) <sup>28</sup>	DSM-IV	PBMCs	IFA, RT-qPCR	Ab, RNA	0	98	0	60	0.61	0.01–31.36	2.73	**	*	*	
	Hornig M et al. (2012) <sup>16</sup>	DSM-IV	BL	RT-qPCR	RNA	0	80	0	80	1.00	0.02–51.01	2.73	****	**	***	
	HSV-1 (HHV-1)	Pokorny AD et al. (1973) <sup>12</sup>	DSM-I	SE	CF	Ab	54	8	35	3	0.58	0.14–2.33	55.45	***	**	2.26 (1.08–4.71; P = 0.030)
		Lycke E et al. (1974) <sup>18</sup>	DSM-I	SE	CF	Ab	31	4	89	51	4.44	1.48–13.30	40.28	**	*	**
		Carrier et al. (1987) <sup>35</sup>	DSM-IV	BR	HIB	DNA	0	10	0	21	2.05	0.04–110.55	3.15	****	*	*
		Conejero-Goldberg C et al. (2003) <sup>23</sup>	DSM-IV	BR	N-PCR, HIB	DNA	0	3	0	26	7.57	0.13–445.73	1.12	***	*	*
		Conejero-Goldberg C et al. (2003) <sup>23</sup>	DSM-IV	BR	N-PCR, HIB	DNA	0	3	0	26	7.57	0.13–445.73	1.12	***	*	* P = 0.330



Table 1 | Continued

Microorganism	Study	Diagnostic criteria	Sample	Technique	Determination	Descriptive statistics				Inferential statistics			Quality			
						Cases		Controls		OR	95%CI	Weight (%)	S	C	E	Global OR
						+	-	+	-							
VZV (HHV-3)	Lycke E et al. (1974) <sup>18</sup>	DSM-I	SE	CF	Ab	19	16	52	88	2.01	0.95–4.25	95.7	**	*	**	2.07 (1.01–4.28; P = 0.048)
	Carter et al. (1987) <sup>35</sup>	DSM-III	BR	HIB	DNA	0	10	0	21	2.05	0.04–110.55	3.2	****	*	*	
	Conejero-Goldberg C et al. (2003) <sup>23</sup>	DSM-IV	BR	HIB	DNA	0	3	0	26	7.57	0.13–445.73	1.1	***	*	*	
EBV (HHV-4)	Amsterdam JD et al. (1986) <sup>38</sup>	DSM-IV	SE	IF	Ab	9	9	13	13	1.00	0.30–3.33	24.18	***	**	***	1.99 (1.21–3.28; P = 0.007)
	Conejero-Goldberg C et al. (2003) <sup>23</sup>	DSM-IV	BR	N-PCR, HIB	DNA	0	3	0	26	7.57	0.13–445.73	0.51	***	*	*	
	Johnson N et al. (2011) <sup>20</sup>	EPDS	SE	?	Ab	48	52	30	70	2.15	1.21–3.85	70.94	**	*	**	
CMV (HHV-5)	Haeri S et al. (2011) <sup>19</sup>	DSM-IV	SE	ELISA	Ab	99	1	96	4	4.13	0.45–37.57	4.37	**	*	*	
	Lycke E et al. (1974) <sup>18</sup>	DSM-I	SE	CF	Ab	24	11	76	64	1.84	0.84–4.04	95.68	**	*	**	1.91 (0.89–4.09; P = 0.096)
	Carter et al. (1987) <sup>35</sup>	DSM-IV	BR	HIB	DNA	0	10	0	21	2.05	0.04–110.55	3.19	****	*	*	
HHV-6	Conejero-Goldberg C et al. (2003) <sup>23</sup>	DSM-IV	BR	N-PCR, HIB	DNA	0	3	0	26	7.57	0.13–445.73	1.13	***	*	*	
	Conejero-Goldberg C et al. (2003) <sup>23</sup>	DSM-IV	BR	N-PCR	DNA	0	3	1	25	2.43	0.08–72.05		***	*	*	P = 0.608
	Fellerhoff B et al. (2005) <sup>21</sup>	DSM-IV	BL	PCR	DNA	1	5	1	114	22.80	1.24–419.74	32.04	**	**	**	11.02 (1.53–79.39; P = 0.017)
<i>C. pneumoniae</i>	Fellerhoff B et al. (2007) <sup>22</sup>	DSM-IV	BL	PCR	DNA	0	4	4	221	5.47	0.25–117.48	67.96	**	**	**	
	Fellerhoff B et al. (2005) <sup>21</sup>	DSM-IV	BL	PCR	DNA	1	5	6	109	3.63	0.36–36.20	59.96	**	**	**	3.32 (0.54–20.44; P = 0.196)
	Fellerhoff B et al. (2007) <sup>22</sup>	DSM-IV	BL	PCR	DNA	0	4	8	217	2.84	0.14–57.16	40.04	**	**	**	
<i>C. psittaci</i>	Fellerhoff B et al. (2005) <sup>21</sup>	DSM-IV	BL	PCR	DNA	0	6	2	113	3.49	0.15–80.49	73.07	**	**	**	5.23 (0.55–49.28; P = 0.149)
	Fellerhoff B et al. (2007) <sup>22</sup>	DSM-IV	BL	PCR	DNA	0	4	2	223	9.93	0.41–238.04	26.93	**	**	**	
	Fariidullah Shah et al. (2004) <sup>38</sup>	DSM-IV	BL	ELISA	Ag	3	132	71	1897	0.61	0.19–1.95	53.4	**	**	**	9.06 (0.026–3192.90; P = 0.461)
<i>T. gondii</i>	Alvarado Esquivel C (2005) <sup>59</sup>	DSM-IV	SE	ELISA	Ag, Ab	0	2	2	2505	200.44	7.54–5326.21	46.6	**	**	**	
	Conejero-Goldberg C et al. (2003) <sup>23</sup>	DSM-IV	BR	N-PCR	DNA	0	3	0	26	7.57	0.13–445.73	1.28	***	*	*	1.36 (0.58–3.22; P = 0.483)
	Alvarado-Esquivel C et al. (2006) <sup>60</sup>	DSM-IV	SE	ELISA	Ab	1	2	16	164	5.13	0.44–59.67	3.96	***	**	*	
	Ceinkaya Z et al. (2007) <sup>61</sup>	DSM-IV	SE	ELISA	Ab	12	38	11	39	1.12	0.44–2.84	94.76	**	*	**	



Table 1 | Continued

Microorganism	Study	Diagnostic criteria	Sample	Technique	Determination	Descriptive statistics				Inferential statistics				Quality			
						Cases		Controls		OR	95%CI	Weight (%)	S	C	E	Global OR	(95% CI; P-value)
						+	-	+	-								
HCV	Faridullah Shah et al. (2004) <sup>58</sup>	DSM-IV	BL	ELISA	Ab	31	104	124	1844	4.43	2.85–6.89	**	**	**	P < 0.001		
JCV	Carter et al. (1987) <sup>35</sup>	DSM-IV	BR	HIB	DNA	0	10	0	21	2.00	0.11–35.09	****	*	*	P = 1.000		
BKV	Carter et al. (1987) <sup>35</sup>	DSM-IV	BR	HIB	DNA	0	10	0	21	2.00	0.11–35.09	****	*	*	P = 1.000		
Measles virus	Lycke E et al. (1974) <sup>18</sup>	DSM-I	SE	CF	Ab	14	21	84	56	0.44	0.21–0.95	**	*	**	P = 0.033		

Abbreviations: EPDS, Edinburgh Depression Scale; DSM, Diagnostic and Statistical Manual of Mental Disorders; CCMD-3, Classification and Diagnostic Criteria of Mental Disorders in China; HHV-1, herpes simplex virus-1; HHV-2 (HSV2), herpes simplex virus-2; HHV-3 (VZV), varicellozoster virus; HHV-4 (EBV), Epstein-Barr virus; HHV-5 (CMV), cytomegalovirus; HHV-6, roseolovirus; HBV, hepatitis B virus; BDV, Borna disease virus; C. trachomatis, Chlamydia trachomatis; C. pneumoniae, Chlamydia pneumoniae; C. psittaci, Chlamydia psittaci; T. gondii, Toxoplasma gondii; HCV, hepatitis C virus; JCV, John Cunningham virus; BKV, BK virus; SE, serum; PL, plasma; BR, brain biopsy; BL, blood; PBMCs, peripheral blood mononuclear cells; PCR, polymerase chain reaction; N-PCR, nested-polymerase chain reaction; RT-PCR, reverse transcriptase polymerase chain reaction; N-RT-PCR, nested reverse transcriptase polymerase chain reaction; RT-qPCR, real-time reverse transcriptase polymerase chain reaction; HIB, hybridization; ELISA, enzyme-linked immunosorbent assay; WB, Western blot; ECLIA, electrochemiluminescence immunoassay; FCM, flow cytometric analysis; ELA, enzyme immunoassay; IF, immunofluorescence assay; IP, immunoprecipitation; CF, complement fixation antibodies; NT, neutralizing antibodies; ?, unknown; DNA, deoxyribonucleic acid; RNA, ribonucleic acid; CC, circulating immune complexes; Ag, antigen; Ab, antibody; +, positive; -, negative; S, Selection; C, Comparability; E, Exposure. Asterisks indicate the level of study quality from low quality (\*) to [\*\*\*\*] high quality.

3.32; CI 95%: 0.54–20.44;  $P = 0.196$ ; Fig. 4B) and *C. psittaci* (OR = 5.23; CI 95%: 0.55–49.28;  $P = 0.149$ ; Fig. 4C), no significant association was observed between infection with these two *Chlamydiaceae* species and depression.

**Other infectious agents.** As to hepatitis B virus (HBV), no significant differences were found (OR = 9.06; CI 95%: 0.026–3192.90;  $P = 0.461$ ) from the analysis of two low-quality studies that compared HBV infection in depressed patients and healthy controls (Fig. 5A, Table 1). With regard to *T. gondii*, three studies focused on the possible relationship between *T. gondii* infection and depression by comparing the detection of infection markers in samples of depressed patients and healthy controls (Fig. 5B, Table 1). Conejero-Goldberg et al.<sup>23</sup> was limited to post-mortem brain tissue samples, and therefore, included a smaller number of cases and controls; this study was also of lower quality. After combining the different studies, no significant association was found between *T. gondii* parasitization and depression (OR = 1.36; CI 95%: 0.58–3.22;  $P = 0.483$ ). With respect to the remaining infectious agents, results from the individual studies that analyzed the relationships between depression and infection with the hepatitis C virus (HCV), the human polyoma virus John Cunningham virus (JCV), the papovavirus BK virus (BKV), and the measles virus are also provided (Table 1).


## Discussion

From the 28 included studies in this systematic review and meta-analysis, 16 infectious agents were discovered in both depressed patients and healthy controls. The majority of included studies focused on BDV, the HHV family, the *Chlamydiaceae* family, *T. gondii*, and HBV. Scattered reports on HCV, JCV, BKV, and measles virus were also included.

Pooled analysis revealed that the majority of the 16 infectious agents were not significantly associated with depression. However, there were statistically significant associations between depression and infection with BDV, HSV-1, VZV, EBV, and *C. trachomatis*.

BDV, a neurotropic, non-cytolytic, non-segmented, negative-stranded non-retroviral RNA virus<sup>24</sup>, infects a variety of animal species, including primates<sup>25</sup> and tree shrews<sup>26</sup>. BDV displays a predilection for infecting the limbic system and hippocampus<sup>27</sup>, two brain regions which play important roles in affective disorders such as depression. Researchers have attempted to clarify the relationship between BDV infection and depression in numerous studies using different populations and diverse techniques; nonetheless, the relationship between BDV infection and depression remains controversial. For instance, Na<sup>28</sup> and Hornig<sup>16</sup> obtained negative results from RT-qPCR of peripheral blood mononuclear cells (PBMCs) and blood; however, persistent BDV seropositivity has been repeatedly demonstrated in a high percentage of depression patients<sup>15,29,30</sup>. Through our pooled analysis, we found that individuals who suffer from depression are 3.25 times more likely to be infected by BDV. This finding indicates that a statistically significant association between BDV infection and depression exists and requires further investigation.

HSV-1 research with respect to depression has been typically descriptive in nature and has been based on two approaches: (i) serological tests showing antibody prevalence in depressed patients and healthy controls, and (ii) brain tissue sampling to ascertain whether the presence of HSV-1 in brain cells is associated with depression. These previous studies, save one<sup>18</sup>, have shown no conclusive findings<sup>31,32</sup>. In this study, a significant association between HSV-1 infection and depression was found. This may be due to the limitations inherent in the human brain tissue studies used in this meta-analysis. For example, after HSV-1 infection, various brain areas may have differing, scant distributions of HSV-1 particles, and with current techniques, it is difficult to detect small quantities



**Figure 2** | Forest plot of studies comparing Borna disease virus (BDV) infection between depressed patients and healthy controls. BDV infection was shown to have a statistically significant association with depression.

of HSV-1 particles. Additionally, post-biopsy brain tissue processing may have affected the viral findings.

Regarding VZV, chickenpox in children has been shown to produce neurological damage in addition to viral encephalitis<sup>33</sup>. Furthermore, major depression has been associated with a marked decline in VZV-specific cellular immunity<sup>34</sup>. These previous studies<sup>23,35</sup>, the lack of association between VZV infection and depression observed here may partly be due to the use of brain tissue for viral DNA detection, which has provided negative results in all participants assessed by this method. Therefore, detection of different tissue samples by various methods should be performed.

Several studies have focused on the relationship between EBV and depression<sup>31,36,37</sup>. Amsterdam et al.<sup>38</sup> showed no association between unrecognized chronic active EBV infection and depression; moreover, Conejero-Goldberg et al.<sup>23</sup> also failed to demonstrate an association between EBV infection and depression. However, the titers of antibodies to EBV have been shown to be significantly higher in psychiatric patients than controls<sup>31</sup>. Most notably, antibodies to EBV viral capsid antigen (EBV-VCA) have been detected in the cerebrospinal fluid (CSF) of psychiatric patients<sup>31</sup>. In addition, a direct association between EBV reactivation and maternal depression has been found among women undergoing first-trimester genetic screening<sup>19</sup>. With respect to the current study, the significant association between EBV infection and depression reported here is strongly dependent on the association reported by Johnson (n = 200)<sup>20</sup> and Haeri (n = 200)<sup>19</sup>, which were the largest EBV studies by sample size as compared to the aforementioned studies by Amsterdam et al.<sup>38</sup> (n = 44) and Conejero-Goldberg et al.<sup>23</sup> (n = 29) (Table 1). These findings suggest that smaller sample-sized studies tend to produce negative results, and identifying a significant association between EBV infection and depression may require a sufficiently large sample size.

Only one study explored the association between HSV-2 infection and depression, which failed to show a significant association between the presence of HSV-2 DNA in brain tissue and depression. Although there were no apparent differences in the mean HSV-2 IgG antibody titers between depressed patients and healthy controls in the current study<sup>32</sup>, previous research has shown that maternal exposure to HSV-2 is associated with an increased risk for psychosis among adult offspring<sup>9</sup>. This fact may be attributed to the heightened

risk of HSV-2 transmission to infants exposed to asymptomatic shedding at delivery<sup>39</sup>. These previous findings suggest that HSV-2 infection at childbirth may play a role in the later development of depression; thus, further investigation on this issue is required.

CMV is a ubiquitous virus, with an especially high prevalence in lower socioeconomic status populations<sup>18</sup>. Individuals with higher CMV-specific antibody titres are more likely to be depressed and experience more overall psychological morbidity, suggesting that symptoms of depression may induce CMV reactivation<sup>40</sup>. Our negative result may be attributed to the use of brain tissue samples for the detection of viral DNA that may have been degraded.


One out of five depressed patients carry *C. trachomatis* DNA, which far exceeds the prevalence in healthy individuals, and indicates a significant association between *C. trachomatis* infection and depression. Interestingly, *C. trachomatis* produces a sexually transmitted disease (STD) as opposed to *C. pneumoniae* and *C. psittaci*, which both produce pneumonia<sup>41</sup>. Although the causal nature of the association between increased depressive symptoms and STDs has not been discerned, sexually risky behaviors may be related to dispositional characteristics, such as impulsiveness, sensation seeking, or a desire for unconventionality, that can be associated with substance abuse and depression<sup>42</sup>.

This systematic review and meta-analysis showed no significant association between HBV infection and depression. Several studies have reported that mentally ill patients have a higher prevalence of HBV infection<sup>43,44</sup>. Unfortunately, few studies have directly examined HBV infection among depression patients with comparable healthy controls. Therefore, future research should focus on the possible relationship between HBV infection and depression.


*T. gondii* is an obligate intracellular protozoan parasite infecting one-third of the world population and dormantly resides in the brains of immunocompetent hosts<sup>45</sup>. Higher *T. gondii* immunoglobulin G titers in pregnant women have been associated with depression during pregnancy<sup>46</sup>, and subclinical reactivation of *T. gondii* or immune responses to *T. gondii* have been shown worsen mood in pregnant women. From one case report, the response to antidepressant treatment improved only after adequate treatment for toxoplasma<sup>47</sup>. Nonetheless, according to the data obtained in this meta-analysis, no significant relationship exists between *T. gondii* seropositivity and recurrent mood disorder<sup>45</sup>.




**A**




**B**



**C**



**D**




**Figure 3 | Forest plot of studies comparing human herpes virus (HHV) infections between depressed patients and healthy controls. (A) herpes simplex virus-1 (HSV-1, HHV-1), (B) varicella zoster virus (VZV, HHV-3), (C) Epstein-Barr virus (EBV, HHV-4), and (D) cytomegalovirus (CMV, HHV-5). Only HSV-1, VZV, EBV infection was shown to have a statistically significant association with depression.**

Finally, four viruses (HCV, JCV, BKV, and measles virus) were analyzed to determine their possible association with depression. Only two, HCV and measles virus, were shown to have a statistically


significant association with depression ( $P < 0.05$ ). However, as these studies were one-of-a-kind and anecdotal, we were unable to draw definitive conclusions about these virus' relationship with depression.




A



B



C



**Figure 4** | Forest plot of studies comparing *Chlamydiaceae* infections between depressed patients and healthy controls. (A) *C. trachomatis*, (B) *C. pneumoniae*, and (C) *C. psittaci*. Only *C. trachomatis* infection was shown to have a statistically significant association with depression.

Based on above results, the directionality of the association between infection and depression should be concerned. We speculate that there might possibly be a causal relationship between BDV and the etiology of depression. The indirect evidence is that the overall response rate of the amantadine augmentation in the BDV-infected patients with regard to depressive symptoms was 68% after a mean of 2.9 weeks of treatment. In addition, the decrease of depression tended to correspond with the decrease in viral activity<sup>48</sup>. However, until now, there are not enough evidences that explain the directionality of the association between the other four microorganism (HSV-1, VZV, EBV, and *C. trachomatis*) and depression. Taking into account the selection bias, which come from the controls in the included studies were not completely enrolled the very same source population of cases (Supplement), thus, more researches correspond to the nested case/control (CC) study design with large sample size should be performed to cope with this problem in the future.

## Methods

**Literature search strategy.** This study was composed of two components: a qualitative systematic review followed by a quantitative meta-analysis. A systematic review, by definition, implies an epidemiologic description of previously published articles that regards individual studies as “subjects”. A computerized literature search


was conducted up to May 2013 using Medline (PubMed), ISI Web of Knowledge, PsycINFO, and the Cochrane Library. No race restriction was utilized. The following logical combinations of search terms were used: (“depression”, “depressive”, “depressed”, OR depression\*) AND ([“virus” OR virus\*] OR [“bacterium”, “bacteria”, OR bacteria\*] OR [“fungus” OR fungi\*] OR [“parasite” OR parasite\*]). Reference lists of all discovered articles were examined for identification of additional eligible studies.

**Inclusion and exclusion criteria.** Included studies must have (i) enrolled patients with a current diagnosis of unipolar depression, consisting of either a primary depressive episode or recurrent depressive disorder, with the specific exclusion of patients with manic episodes, bipolar disorder, and other unclearly defined mood or affective disorders; (ii) enrolled controls who were defined as healthy individuals or those characterized by the absence of any history of psychiatric or neurological disease; and (iii) examined biochemical markers in both patients and controls. Excluded studies included non-controlled studies, animal studies, reviews, studies which did not present their results in an appropriate and/or explicit manner, and those that did not assess infectious agent(s).


**Selection of studies, data extraction, and management.** A customized data extraction form was used. Three authors (XL, XZ and YL) independently performed the database searches, reviewed each of the retrieved abstracts, selected those that appeared to meet the study’s inclusion criteria, and reviewed each of the selected manuscripts in full. Where a study met the inclusion criteria, they independently extracted the data from each study. The following information was extracted: microorganism, first author name, publication year, diagnostic criteria for unipolar depression, sample of detection, technique, biomarker of determination, descriptive



A



B



**Figure 5 | Forest plot of studies comparing two other microorganisms infections between depressed patients and healthy controls. (A) hepatitis B virus, (B) *Toxoplasma gondii*. Neither of them infection was shown to have a statistically significant association with depression.**

results in each group (Table 1). All authors reviewed and agreed on the study inclusion and exclusion criteria, and on the selected manuscripts. Any disagreement was resolved by consensus or third-party adjudication (XL). Study quality was assessed using the Newcastle-Ottawa Quality Assessment Scale ([http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.htm](http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm); updated 10 February 2010).

**Statistical analysis.** The summary odds ratio (OR) was used as the effect parameter for this meta-analysis, and a 95% confidence interval (CI) was used to interpret the results. When the number of studies under analysis was greater than or equal to three (although five may be better), heterogeneity was assessed using the  $\chi^2$  test and  $I^2$ . A  $P$ -value of  $\leq 0.10$  was deemed statistically significant, and there were not substantial heterogeneity if a 95% CI for the  $I^2$  index contains the zero percentage.  $I^2$  values of 25%, 50%, and 75% represented low, moderate, and high degree of inconsistency, respectively. In cases of low heterogeneity for outcome data, a fixed-effect model was used for analysis; otherwise, a random-effect model was used. For  $I^2$  values greater than 75%, strong heterogeneity dictated the performance of an additional meta-regression using the Restricted Maximum Likelihood (REML) method. In such cases and if the number of studies to be included in each subgroup was big enough (greater than or equal to three), a more detailed sub-analysis of the different subgroups was performed. Finally, Begg's and Egger's tests were used in order to check for any particular publication biases and their magnitude. Data obtained from the included studies were analyzed using the R version 3.0.1 statistical package. All tests were two-sided, and a  $P < 0.05$  was deemed statistically significant unless otherwise specified.

- Ustun, T. B. *et al.* Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. WHO/NIH Joint Project CAR Study Group. *Lancet* **354**, 111–115 (1999).
- Murray, C. J. & Lopez, A. D. Evidence-based health policy—lessons from the Global Burden of Disease Study. *Science (New York, N.Y.)* **274**, 740–743 (1996).
- Nestler, E. J. *et al.* Neurobiology of depression. *Neuron* **34**, 13–25 (2002).
- Lohoff, F. W. Overview of the genetics of major depressive disorder. *Curr Psychiatry Rep* **12**, 539–546, doi:10.1007/s11920-010-0150-6 (2010).
- Brooks-Gunn, J. & Duncan, G. J. The effects of poverty on children. *The future of children*, 55–71 (1997).
- Mason, L. H., Mathews, M. J. & Han, D. Y. Neuropsychiatric symptom assessments in toxic exposure. *Psychiatr Clin North Am* **36**, 201–208, doi:10.1016/j.psc.2013.02.001 (2013).
- Schlossberg, K., Massler, A. & Zalsman, G. Environmental risk factors for psychopathology. *Isr J Psychiatry Relat Sci* **47**, 139 (2010).
- Sayers, I. Low spirits after virus infections. *BMJ* **2**, 440 (1976).

- Buka, S. L., Cannon, T. D., Torrey, E. F. & Yolken, R. H. Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. *Biol Psychiatry* **63**, 809–815, doi:10.1016/j.biopsych.2007.09.022 (2008).
- Halonon, P. E., Rimon, R., Arohonka, K. & Jantti, V. Antibody levels to herpes simplex type I, measles and rubella viruses in psychiatric patients. *Br J Psychiatry* **125**, 461–465 (1974).
- Allen, A. D. & Tilkian, S. M. Depression correlated with cellular immunity in systemic immunodeficient Epstein-Barr virus syndrome (SIDES). *J Clin Psychiatry* **47**, 133–135 (1986).
- Pokorny, A. D., Rawls, W. E., Adam, E. & Mefferd, R. B., Jr. Depression, psychopathy, and herpesvirus type I antibodies. Lack of relationship. *Arch Gen Psychiatry* **29**, 820–822 (1973).
- Sinanian, K. & Hillary, I. Post-influenza depression. *Br J Psychiatry* **138**, 131–133 (1981).
- King, D. J. *et al.* A survey of serum antibodies to eight common viruses in psychiatric patients. *Br J Psychiatry* **147**, 137–144 (1985).
- Fu, Z. F. *et al.* Detection of Borna disease virus-reactive antibodies from patients with affective disorders by western immunoblot technique. *J Affect Disord* **27**, 61–68 (1993).
- Hornig, M. *et al.* Absence of evidence for bornavirus infection in schizophrenia, bipolar disorder and major depressive disorder. *Mol Psychiatry* **17**, 486–493, doi:10.1038/mp.2011.179 (2012).
- Bode, L., Riegel, S., Lange, W. & Ludwig, H. Human infections with Borna disease virus: seroprevalence in patients with chronic diseases and healthy individuals. *J Med Virol* **36**, 309–315 (1992).
- Lycke, E., Norrby, R. & Roos, B. E. A serological study on mentally ill patients with particular reference to the prevalence of herpes virus infections. *Br J Psychiatry* **124**, 273–279 (1974).
- Haeri, S. *et al.* Maternal depression and Epstein-Barr virus reactivation in early pregnancy. *Obstet Gynecol* **117**, 862–866, doi:10.1097/AOG.0b013e31820f3a30 (2011).
- Johnson, N. *et al.* Depression in pregnancy: is there an association with Epstein-Barr virus (EBV) reactivation? *Am J Obstet Gynecol* **204**, S322–S322, doi:10.1016/j.jog.2010.10.848 (2011).
- Fellerhoff, B., Laumbacher, B. & Wank, R. High risk of schizophrenia and other mental disorders associated with chlamydial infections: hypothesis to combine drug treatment and adoptive immunotherapy. *Med Hypotheses* **65**, 243–252, doi:10.1016/j.mehy.2005.03.013 (2005).
- Fellerhoff, B., Laumbacher, B., Mueller, N., Gu, S. & Wank, R. Associations between Chlamydia infections, schizophrenia and risk of HLA-A10. *Mol Psychiatry* **12**, 264–272, doi:10.1038/sj.mp.4001925 (2007).
- Conejero-Goldberg, C., Torrey, E. F. & Yolken, R. H. Herpesviruses and *Toxoplasma gondii* in orbital frontal cortex of psychiatric patients. *Schizophr Res* **60**, 65–69 (2003).



24. de la Torre, J. C. [Family Bornaviridae] *Virus taxonomy: classification and nomenclature of viruses: seventh report of the International Committee on Taxonomy of Viruses* [Regenmortel, M. (ed.)] [531–538] (Academic Press, London, 2000).
25. Stütz, L., Krey, H. & Ludwig, H. Borna disease in rhesus monkeys as a models for uveo-cerebral symptoms. *J Med Virol* **6**, 333–340 (1981).
26. Sprankel, H., Richarz, K., Ludwig, H. & Rott, R. Behavior alterations in tree shrews (*Tupaia glis*, Diard 1820) induced by Borna disease virus. *Med Microbiol Immun* **165**, 1–18 (1978).
27. Wagner, K., Ludwig, H. & Paulsen, J. Fluorescence serological demonstration of Borna virus antigen. *Berl Munch Tierarztl* **81**, 395–396 (1968).
28. Na, K. S., Tae, S. H., Song, J. W. & Kim, Y. K. Failure to detect borna disease virus antibody and RNA from peripheral blood mononuclear cells of psychiatric patients. *Psychiatry Investig* **6**, 306–312, doi:10.4306/pi.2009.6.4.306 (2009).
29. Bode, L. *et al.* Borna disease virus-specific circulating immune complexes, antigenemia, and free antibodies--the key marker triplet determining infection and prevailing in severe mood disorders. *Mol Psychiatr* **6**, 481–491, doi:10.1038/sj.mp.4000909 (2001).
30. Bode, L., Zimmermann, W., Ferszt, R., Steinbach, F. & Ludwig, H. Borna disease virus genome transcribed and expressed in psychiatric patients. *Nat Med* **1**, 232–236 (1995).
31. Gotlieb-Stematsky, T. *et al.* Antibodies to Epstein-Barr virus, herpes simplex type 1, cytomegalovirus and measles virus in psychiatric patients. *Arch Virol* **67**, 333–339 (1981).
32. Amsterdam, J. D. & Hernz, W. J. Serum antibodies to herpes simplex virus types I and II in depressed patients. *Biol Psychiat* **34**, 417–420 (1993).
33. Rianza, G. M., de la Torre, E. M., Mencía, B. S., Molina, C. J. & Tamariz-Martel, M. A. Complications of varicella in children. *An Esp Pediatr* **50**, 259 (1999).
34. Irwin, M. *et al.* Cellular immunity to varicella-zoster virus in patients with major depression. *J Infect Dis* **178 Suppl 1**, S104–108 (1998).
35. Carter, G. I., Taylor, G. R. & Crow, T. J. Search for viral nucleic acid sequences in the post mortem brains of patients with schizophrenia and individuals who have committed suicide. *J Neurol Neurosurg Psychiatry* **50**, 247–251 (1987).
36. Greenberg, D. B. Depression, anxiety, and Epstein-Barr virus infection. *Ann Intern Med* **104**, 449 (1986).
37. Cooke, R. G., Warsh, J. J., Hasey, G. M., McLaughlin, B. J. & Jorna, T. Epstein-Barr virus antibodies and severity of depression. *Biol Psychiat* **29**, 621–623 (1991).
38. Amsterdam, J. D. *et al.* Serum antibodies to Epstein-Barr virus in patients with major depressive disorder. *Am J Psychiatry* **143**, 1593–1596 (1986).
39. Buka, S. L. *et al.* Maternal infections and subsequent psychosis among offspring. *Arch Gen Psychiatry* **58**, 1032–1037 (2001).
40. Phillips, A. C., Carroll, D., Khan, N. & Moss, P. Cytomegalovirus is associated with depression and anxiety in older adults. *Brain Behav Immun* **22**, 52–55, doi:10.1016/j.bbi.2007.06.012 (2008).
41. Deborah, D. [Lessons and Challenges Arising from the “First Wave of Chlamydia Genome Sequencing”] *Chlamydia: genomics and pathogenesis* [Patrik, M. (ed.)] [14] (Horizon Scientific Press, 2006).
42. Shrier, L. A. *et al.* Depressive symptoms and sexual risk behavior in young, chlamydia-infected, heterosexual dyads. *J Adolesc Health* **45**, 63–69, doi:10.1016/j.jadohealth.2008.11.016 (2009).
43. Prats, F., Porta Serra, M., Yazbeck, H., Herrera, R. & Gasso, J. M. The prevalence of serological markers for the human immunodeficiency virus and the hepatitis B virus in a psychiatric hospital. *Gac Sanit* **4**, 179–183 (1990).
44. Franson, T. R., Ksobiech, L. J. & Simonsen, H. W. Prevalence of hepatitis B carriers in a mental health in-patient facility: implications for employee screening and vaccination. *Psychiatr Hosp* **17**, 81–83 (1986).
45. Arling, T. A. *et al.* Toxoplasma gondii antibody titers and history of suicide attempts in patients with recurrent mood disorders. *J Nerv Ment Dis* **197**, 905–908, doi:10.1097/NMD.0b013e3181c29a23 (2009).
46. Groer, M. W. *et al.* Prenatal depression and anxiety in Toxoplasma gondii-positive women. *Am J Obstet Gynecol* **204**(433), e431–437, doi:10.1016/j.ajog.2011.01.004 (2011).
47. Kar, N. & Misra, B. Toxoplasma seropositivity and depression: a case report. *BMC psychiatry* **4**, 1, doi:10.1186/1471-244x-4-1 (2004).
48. Dietrich, D. E. *et al.* Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. *Bipolar Disord* **2**, 65–70 (2000).
49. Amsterdam, J. D. *et al.* Borna disease virus. A possible etiologic factor in human affective disorders? *Arch Gen Psychiatry* **42**, 1093–1096 (1985).
50. Igata-Yi, R. *et al.* Borna disease virus and the consumption of raw horse meat. *Nat Med* **2**, 948–949 (1996).
51. Salvatore, M., Morzunov, S., Schwemmler, M. & Lipkin, W. I. Borna disease virus in brains of North American and European people with schizophrenia and bipolar disorder. Bornavirus Study Group. *Lancet* **349**, 1813–1814 (1997).
52. Fukuda, K. *et al.* Immunological and PCR analyses for Borna disease virus in psychiatric patients and blood donors in Japan. *J Clin Microbiol* **39**, 419–429, doi:10.1128/jcm.39.2.419-429.2001 (2001).
53. Lebain, P. *et al.* Borna disease virus and psychiatric disorders. *Schizophr Res* **57**, 303–305 (2002).
54. Zou, D. Z. *et al.* Detection of Borna disease virus P24 RNA from peripheral blood mononuclear cells in psychiatric patients. *Chinese journal of psychiatry* **36**, 228–230 (2003) (in Chinese).
55. Wang, Z. H., Xie, P., Han, Y. X. & Zhan, J. Study on molecular epidemiology of Borna disease virus in Ningxia and vicinal regions. *Chinese journal of epidemiology* **27**, 479–482 (2006) (in Chinese).
56. Zhao, L. B. *et al.* Molecular Biological Research on Borna Disease Virus Infection in Depressive Patients of Chongqing. *Chinese journal of nervous and mental diseases* **33**, 18–22 (2007).
57. Flower, R. L. *et al.* Human Borna disease virus infection in Australia: serological markers of infection in multi-transfused patients. *APMIS. Supplementum*, 89–93 (2008).
58. Shah, F. & Dar, S. I. Prevalence of Hepatitis C in depressed population. *Pak J Med Res* **43**, 200–202 (2004).
59. Alvarado Esquivel, C., Arreola Valenzuela, M. A., Mercado Suarez, M. F. & Espinoza Andrade, F. Hepatitis B virus infection among inpatients of a psychiatric hospital of Mexico. *Clin Pract Epidemiol Ment Health* **1**, 10, doi:10.1186/1745-0179-1-10 (2005).
60. Alvarado-Esquivel, C. *et al.* Seroepidemiology of Toxoplasma gondii infection in psychiatric inpatients in a northern Mexican city. *BMC Infect Dis* **6**, 178, doi:10.1186/1471-2334-6-178 (2006).
61. Cetinkaya, Z., Yazar, S., Gecici, O. & Namli, M. N. Anti-Toxoplasma gondii antibodies in patients with schizophrenia--preliminary findings in a Turkish sample. *Schizophr Bull* **33**, 789–791, doi:10.1093/schbul/sbm021 (2007).

## Acknowledgments

This work was supported by the National Basic Research Program of China (973 Program) (Grant No. 2009CB918300), the National Natural Science Foundation of China (Grant No. 30900456 and 21175099), and the Natural Science Foundation Project of Chongqing (CSTC, 2008BB5238 and 2010BB5393). The funders had no role in study design, data collection and analysis, publication decisions, or manuscript preparation. We sincerely thank Dr. N.D. Melgiri for his assistance in editing and proofreading the manuscript.

## Author contributions

Conceived and designed the experiments: P.X., X.W., L.Z. and Y.L. Performed the experiments: X.L., X.Z. and Y.L. Analyzed the data: X.W., M.W. and L.Y. Contributed reagents/materials/analysis tools: L.Z. and S.F. Wrote the paper: X.W., L.Z., Y.L. and X.L.

## Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Wang, X. *et al.* Meta-Analysis of Infectious Agents and Depression. *Sci. Rep.* **4**, 4530; DOI:10.1038/srep04530 (2014).



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images in this article are included in the article's Creative Commons license, unless indicated otherwise in the image credit; if the image is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the image. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>